Who Supplies Esomeprazole to India from UNITED STATES

Importing finished pharmaceutical formulations containing Esomeprazole into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs be registered and approved before distribution. Importers must obtain an Import Registration Certificate and an Import License from CDSCO. The registration process involves submitting Form 40 or 41, along with necessary documents such as the Free Sale Certificate, Certificate of Pharmaceutical Product (CoPP), and a copy of the manufacturing license. The timeline for obtaining approval varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory workload. For Esomeprazole formulations under HS Code 30049039, specific requirements include stability data (preferably ICH Zone IV), a Certificate of Analysis (CoA), and evidence of Good Manufacturing Practice (GMP) compliance. Additionally, a No Objection Certificate (NOC) from the manufacturer may be required to confirm the authenticity and quality of the product.

Imported Esomeprazole formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian standards. Each batch requires a Certificate of Analysis (CoA) confirming the product's quality, purity, and potency. Stability studies should be conducted under ICH Zone IV conditions to demonstrate the product's shelf-life in India's climate. The product must conform to the Indian Pharmacopoeia (IP) standards or demonstrate bioequivalence to the innovator product. Upon arrival, customs drug inspectors perform port inspections, which may include sampling for laboratory analysis. If a batch fails quality testing, it may be rejected, destroyed, or re-exported, depending on the severity of the non-compliance.

Between 2024 and 2026, CDSCO has implemented stricter regulations for importing pharmaceutical products to enhance drug safety and efficacy. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the volume of finished formulation imports. Bilateral agreements between India and the United States have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for U.S. manufacturers.

India imports finished Esomeprazole formulations primarily due to the demand for patented or branded products not manufactured domestically, specific dosage forms, and formulations with unique delivery mechanisms. The domestic pharmaceutical industry may lack the capacity or technology to produce certain Esomeprazole formulations, leading to reliance on imports. The market size for Esomeprazole in India is substantial, with a growing prevalence of gastrointestinal disorders contributing to increased consumption.

The Basic Customs Duty (BCD) for Esomeprazole formulations under HS Code 30049039 is 10%. A Social Welfare Surcharge (SWS) of 10% is applied on the BCD, resulting in an additional 1% duty. Integrated Goods and Services Tax (IGST) is levied on the assessable value plus applicable customs duties. Anti-dumping duties may apply if the product is found to be dumped in the Indian market. Exemptions or reduced rates may be available under specific trade agreements or government notifications. The total landed duty percentage varies based on the product's assessable value and applicable taxes.

India sources Esomeprazole formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. U.S. manufacturers often hold patents for innovative Esomeprazole formulations, providing a competitive advantage. While other suppliers like China and Germany also export Esomeprazole formulations to India, the United States maintains a significant share due to its advanced pharmaceutical technology and adherence to international quality standards.

India imports Esomeprazole formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. U.S. manufacturers often hold patents for innovative Esomeprazole formulations, providing a competitive advantage. The advanced pharmaceutical technology and adherence to international quality standards in the U.S. make it a preferred source for these formulations.

Compared to other origins like China and the European Union, the United States offers Esomeprazole formulations with superior quality, innovative dosage forms, and compliance with international regulatory standards. While other suppliers may offer competitive pricing, the United States's unique advantage lies in its advanced pharmaceutical technology and consistent product quality.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or regulatory non-compliance in the exporting country. Diversifying suppliers and maintaining buffer stocks can mitigate some of these risks.

1. 1Engage in dual-sourcing strategies to reduce dependency on a single supplier.
2. 2Implement robust inventory planning to manage supply chain disruptions.
3. 3Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Establish minimum order quantities (MOQs) that align with demand forecasts.
5. 5Conduct thorough supplier qualification processes, including audits and compliance checks.

1. 1Obtain a valid Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Submit Form 40 or 41 to CDSCO for registration of the pharmaceutical product.
3. 3Secure an Import License from CDSCO.
4. 4Provide a No Objection Certificate (NOC) from the manufacturer.
5. 5Engage a licensed customs broker for customs clearance.
6. 6Seek an advance ruling from customs for HS Code 30049039 classification, if necessary.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.